Market activity on Wednesday underlined the importance of a US Food and Drug Administration (FDA) approval of a generic drug from Mylan (Nasdaq: MYL).
The Netherlands-incorporated drugmaker won approval for its generic version of Copaxone (glatiramer acetate) at 40mg/mL for a three-times-a-week injection, and the once-daily 20mg/mL injection.
Copaxone is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) and is marketed by Israel’s Teva Pharmaceutical Industries (NYSE: TEVA), which has waged a long legal battle against Mylan in its attempts to hang onto exclusivity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze